Nhytida (Ethinylestradiol, Gestodene)

Ethinylestradiol, the active ingredient in Nhytida, is a combined oral contraceptive presented as an oral tablet for oral use. It works together with gestodene to prevent pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus. The formulation combines ethinyloestradiol with gestodene, providing a low‑dose estrogen‑progestin regimen that aligns with European Union standards for safety and efficacy.

GNH USA supplies Nhytida as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Nhytida, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy. Prevention of pregnancy: provides reliable contraceptive protection by suppressing ovulation, thickening cervical mucus, and altering the endometrium when taken consistently as prescribed. Management of menstrual disorders: can be used to treat dysmenorrhea and irregular menstrual cycles, helping to achieve more predictable bleeding patterns. Acne reduction: the hormonal balance may improve acne in some women by decreasing androgenic activity.

Common Side Effects: - Nausea: mild to moderate stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: occasional mild to moderate headaches. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Mood changes: fluctuations in mood or mild irritability. - Weight gain: slight increase in body weight due to fluid retention. Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins, potentially leading to pulmonary embolism. - Arterial thrombosis: risk of heart attack or stroke, especially in smokers over 35. - Hypertension: significant increase in blood pressure. - Liver tumor: rare benign hepatic adenoma. - Gallbladder disease: inflammation or stones in the gallbladder.

Before prescribing Nhytida, consider the following precautions: - Contraindicated in pregnancy: product is classified as Category X and must not be used. - Avoid in smokers over 35: increased risk of cardiovascular events. - Assess history of thromboembolic disorders: risk of clot formation may be elevated. - Monitor blood pressure regularly: the formulation can cause hypertension. - Evaluate liver function: hepatic disease may affect drug metabolism. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nhytida may interact with several medications. Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampin or rifabutin: can lower plasma levels of ethinylestradiol and gestodene. - Certain antiretrovirals (e.g., efavirenz): may diminish hormonal protection. Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., ampicillin): may slightly decrease effectiveness. - St. John’s wort: herbal inducer that can lower hormone concentrations. - Diuretics: may increase the risk of hypertension when combined with the contraceptive.